STOCK TITAN

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
earnings date

Quoin Pharmaceuticals (NASDAQ: QNRX) will provide a corporate update and release fourth quarter and full-year 2025 financial results before the market opens on Thursday, March 26, 2026.

The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025, per the company.

Loading...
Loading translation...
Argus Mar 19 session
+5.36% close to close 0.7x rel. volume Open Argus
Details

News Market Reaction – QNRX

On Mar 19, the day this news came out, QNRX closed 5.36% above the previous close.

Data tracked by StockTitan Argus for the Mar 19 session.

Key Figures

Earnings release date: March 26, 2026 Fiscal year end: December 31, 2025
Earnings release date
March 26, 2026
Scheduled Q4 and full-year 2025 results release before market open
Fiscal year end
December 31, 2025
Full-year 2025 period to be reported

Historical Context

5 past events · Latest: Mar 11
5 events
  1. Mar 11

    Fast Track designation

    24h Move
    -1.1%

    FDA granted Fast Track status to QRX003 for Netherton Syndrome.

  2. Feb 26

    Awareness campaign

    24h Move
    +0.1%

    NETHERTON NOW campaign update highlighting growing disease awareness metrics.

  3. Jan 27

    Japan ODD submission

    24h Move
    -1.7%

    Submission for Orphan Drug Designation and Fast Track review in Japan.

  4. Jan 20

    Saudi breakthrough filing

    24h Move
    +1.8%

    Filed for Breakthrough Medicine Designation for QRX003 in Saudi Arabia.

  5. Nov 11

    Pipeline expansion

    24h Move
    +41.4%

    Reported achieving target rapamycin loadings and plans for new clinical trials.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026.

The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025.

About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, microcystic lymphatic malformations, venous malformations, angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com

Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Quoin Pharmaceuticals (QNRX) release its Q4 and full-year 2025 results?

Quoin will release Q4 and full-year 2025 results before the market opens on March 26, 2026. According to the company, the release includes an operational update and financial highlights for 2025.

What will Quoin Pharmaceuticals (QNRX) cover in its March 26, 2026 corporate update?

The corporate update will cover operational achievements, recent accomplishments, and 2025 financial highlights. According to the company, the presentation pairs an operational update with the fourth quarter and full-year financial results.

How can investors access Quoin Pharmaceuticals (QNRX) March 26, 2026 announcement?

Investors can access the March 26 announcement via Quoin's investor channels around the market open time. According to the company, results and the corporate update will be released before market open on that date.

Will Quoin Pharmaceuticals (QNRX) provide clinical program updates on March 26, 2026?

Yes, the company indicated the operational update will highlight recent accomplishments, which may include clinical program updates. According to the company, the operational update will summarize key achievements from the quarter.

What date covers the financial results Quoin (QNRX) will report on March 26, 2026?

The financial results cover the fourth quarter and full year ended December 31, 2025. According to the company, both quarter and full-year 2025 financial highlights will be disclosed in the release.

Is the Quoin Pharmaceuticals (QNRX) March 26, 2026 release expected before trading begins?

Yes, the company will release information before the market opens on March 26, 2026. According to the company, the timing is intended to precede the trading day and include operational and financial highlights.

Keep reading